

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kahn et al.

Serial No.: To be assigned

Filed: December 21, 2001

For: OLIGOPEPTIDE TREATMENT OF
ANTHRAX

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 5222US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL740516715US

Date of Deposit with USPS: December 21, 2001

Person making Deposit: Blake Johnson

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above identified patent application as follows:

IN THE CLAIMS:

Please amend claims as follows. Please note that claim amendments are presented here in clean form for clarity, a marked up version of the claim amendments is attached.

4. (Amended) The method according to claim 2 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.

7. (Amended) The method according to claim 1 wherein said inflammatory condition comprises an acute inflammatory condition.

9 (Amended) The method according to claim 1 wherein said molecule is selected from table 6.

10. (Amended) The method according to claim 1 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising an oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.

Please add the following new claims:

17. The method according to claim 3 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.

18. The method according to claim 2 wherein said inflammatory condition comprises an acute inflammatory condition.


19 The method according to claim 2 wherein said molecule is selected from table 6.

20. The method according to claim 2 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising an oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.

Remarks

The Office is respectfully requested to enter the above amendments prior to the calculation of the filing fee in this application. Should the Office determine that additional issues remain which might be resolved by a telephone conference, it is respectfully invited to contact applicants' undersigned attorney.

Respectfully Submitted,



Allen C. Turner
Registration Number 33,041
Attorney for Applicants
TRASKBRITT, PC
P.O. Box 2550
Salt Lake City, Utah 84110
Telephone: (801) 532-1922

Date: December 21, 2001

N:\2183\S222\Preliminary Amendment.wpd

**VERSION WITH MARKINGS TO SHOW CHANGES MADE
IN THE CLAIMS:**

Please amend the claims as follows:

4. (Amended) The method according to claim 2 [or 3] wherein said gene transcription factor comprises a NF-kappaB/Rel protein.
7. (Amended) The method according to [any one of claims 1 to 6]claim 1 wherein said inflammatory condition comprises an acute inflammatory condition.
- 9 (Amended) The method according to [any one of claims 1 to 8]claim 1 wherein said molecule is selected from table 6.
10. (Amended) The method according to [any one of claims 1 to 9]claim 1 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising an oligopeptide or functional analogue thereof capable of reducing production of NO by a cell.